EP179/#734  Postoperative combined chemotherapy and radiotherapy for stage III endometrial cancer: an updated survival analysis of a multicenter retrospective study

• Published in: International journal of gynecological cancer Vol. 33; no. Suppl 4; pp. A149 - A150
• Main Authors: Yoo, Ji Geun, Kim, Jin Hwi, Kim, Chan Joo, Lee, Hae Nam, Song, Min Jong, Park, Dong Choon, Yoon, Joo Hee, Kim, Sang Il, Hur, Soo Young, Lee, Sung Jong
• Format: Journal Article
• Language: English
• Published: Oxford BMJ Publishing Group Ltd 07.11.2023; BMJ Publishing Group LTD
• Subjects: Cancer therapies; Chemotherapy; Endometrial cancer; ePoster Viewing; Survival analysis
• ISSN: 1048-891X; 1525-1438
• DOI: 10.1136/ijgc-2023-IGCS.266

IntroductionOur previous report showed the efficacy and toxicity of adjuvant combination chemotherapy and radiation therapy (CRT) compared with chemotherapy alone (CT) in patients with stage III endometrial cancer. Here we present updated survival data with a median follow-up period of 60.0 months.MethodsMedical records of patients who received standard surgical treatment for stage III endometrial cancer at six hospitals from January 2009 to December 2019 were retrospectively reviewed. Patients who received postoperative adjuvant CRT or CT were included. Disease-free survival (DFS) and overall survival (OS) was compared using Kaplan-Meier method and log-rank test. The data cutoff date was May 1, 2013.ResultsA total of 133 patients were included in the analysis, 80 (60.2%) in the CRT group and 53 (39.8%) in the CT group. In the overall population, 5-year DFS (CRT, 73% vs. CT, 65%, log-rank P = 0.290) and OS (81% vs. 75%, log-rank P = 0.400) rates were similar between treatment groups. In the subgroup of patients with stage IIIC endometrioid endometrial cancer, the CRT group had a significantly longer 5-year DFS rate compared with the CT group (76% vs. 55%, log-rank P = 0.037), but not for OS (81% vs. 71%, log-rank P = 0.450). Multivariable Cox regression analysis identified that CRT was the only independent favorable prognostic factor for DFS in this subgroup (adjusted HR, 0.43 (95% CI 0.19–0.97), P = 0.044). Conclusion/ImplicationsFor patients with stage IIIC endometrioid endometrial cancer, CRT was associated with an improved long-germ DFS compared with CT.Abstract EP179/#734 Figure 1Abstract EP179/#734 Table 1Factors associated with disease-free survival in FIGO stage IIIC endometrioid endometrial cancer